Rigel has an exclusive license and supply agreement with Grifols to commercialize TAVALISSE (fostamatinib disodium hexahydrate) in all potential indications in Europe, Turkey, MENA, Russia and CIS.
The product launched in Europe in July 2020 for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and is marketed under the brand name TAVLESSE® (fostamatinib). It is the first and only spleen tyrosine kinase (SYK) inhibitor approved in Europe for this indication.
Rigel received an upfront cash payment, is eligible for regulatory and commercial milestone payments, and receives tiered royalty payments on net sales of TAVALISSE in the territory.